ASCO 2018 - Results from #35

Viewing 36-55 of 71 articles

ASCO 2018: Radiopharmaceuticals: Emitting the Right Signals in Prostate Cancer

ASCO 2018: Abiraterone Acetate and Prednisone, AAP Plus Degarelix, and Degarelix Alone for Patients with Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy

ASCO 2018: Biochemical Recurrence: Judicious Clinical Management of an Evolving Disease State

ASCO 2018: KEYNOTE-046: ADXS-PSA Plus Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

ASCO 2018: Patient Preference Between Darolutamide and Enzalutamide in Men with Metastatic Castration-resistant Prostate Cancer: ODENZA

ASCO 2018: Precision Risk Stratification and Treatment in Biochemical-Recurrent Prostate Cancer

ASCO 2018: Lifting the Veil on Micrometastatic Disease: Emerging Imaging Strategies in Biochemical Recurrence

ASCO 2018: Relationship of Time to Metastasis and Site of Metastases in Patients with Nonmetastatic CRPC: Results from the Phase 3 SPARTAN Trial

ASCO 2018: Prostate Radiotherapy in Newly-Diagnosed Metastatic Hormone-Sensitive Prostate Cancer

ASCO 2018: Phase II Safety and Tolerability Study of Radium-223 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: CTRIAL-IE (ICORG) 13-21

ASCO 2018: Pembrolizumab Plus Enzalutamide in Metastatic Castration Resistant Prostate Cancer: Extended Follow Up

ASCO 2018: Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

ASCO 2018: Lutetium-177 PSMA617 Theranostics In Metastatic Castrate-Resistant Prostate Cancer: Interim Results of a Phase II Trial

ASCO 2018: Combination of Niclosamide to Target Androgen Receptor Variant 7 and Abiraterone to Target Androgen

ASCO 2018: Results from the PROSPER Study: HRQoL Deterioration and Pain Progression in Men with Non-Metastatic Castration-Resistant Prostate Cancer

ASCO 2018: KEYNOTE-046: ADXS-PSA plus Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

ASCO 2018: Timing of Androgen Deprivation Therapy for Prostate Cancer Patients After Radiation: Planned Combined Analysis of Two Randomized Phase 3 Trials

ASCO 2018: Striking the Right Tone: Optimizing the Use of Social Media During Conferences

ASCO 2018: Phase 2, Randomized, 3-arm Study of Abiraterone Acetate and Prednisone (AAP), AAP Plus Degarelix (Aap+d), and Degarelix Alone for Patients with Biochemically-recurrent Prostate Cancer Following Radical Prostatectomy

ASCO 2018: Phase 2 Randomized Cross-over Trial of Abiraterone + Prednisone vs Enzalutamide for Patients with Metastatic Castration Resistant Prostate Cancer (mCPRC): Results for 2nd-line therapy

1
2
3
4